Avidity Biosciences Inc (NASDAQ: RNA) kicked off on Tuesday, up 0.04% from the previous trading day, before settling in for the closing price of $69.8. Over the past 52 weeks, RNA has traded in a range of $21.51-$70.51.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -34.37%. While this was happening, its average annual earnings per share was recorded -47.06%. With a float of $133.97 million, this company’s outstanding shares have now reached $145.90 million.
Avidity Biosciences Inc (RNA) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Avidity Biosciences Inc is 8.18%, while institutional ownership is 90.63%. The most recent insider transaction that took place on Oct 22 ’25, was worth 105,015. In this transaction Chief Medical Officer of this company sold 2,209 shares at a rate of $47.54, taking the stock ownership to the 38,867 shares. Before that another transaction happened on Oct 15 ’25, when Company’s Chief Human Resources Officer sold 20,000 for $50.15, making the entire transaction worth $1,003,058. This insider now owns 97,130 shares in total.
Avidity Biosciences Inc (RNA) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.65 earnings per share (EPS), higher than consensus estimate (set at -0.72) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -47.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.59% during the next five years compared to -34.37% drop over the previous five years of trading.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Take a look at Avidity Biosciences Inc’s (RNA) current performance indicators. Last quarter, stock had a quick ratio of 9.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 949.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.56, a number that is poised to hit -1.09 in the next quarter and is forecasted to reach -4.72 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
The latest stats from [Avidity Biosciences Inc, RNA] show that its last 5-days average volume of 12.48 million was superior to 2.74 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 97.18%.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 98.41%, which indicates a significant increase from 97.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.41 in the past 14 days, which was lower than the 2.12 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $49.29, while its 200-day Moving Average is $36.66. Now, the first resistance to watch is $69.88. This is followed by the second major resistance level at $69.93. The third major resistance level sits at $69.99. If the price goes on to break the first support level at $69.77, it is likely to go to the next support level at $69.71. The third support level lies at $69.66 if the price breaches the second support level.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
The company with the Market Capitalisation of 10.19 billion has total of 145,903K Shares Outstanding. Its annual sales at the moment are 10,900 K in contrast with the sum of -322,300 K annual income. Company’s last quarter sales were recorded 3,850 K and last quarter income was -157,320 K.
